Publication of prospectus

Oncology Venture Sweden AB ("Oncology Venture") hereby publishes prospectus regarding the rights issue starting March 16, 2017. The prospectus is available via the Company´s (www.oncologyventure.com), AktieTorgets (www.aktietorget.se) and Sedermera Fondkommissions (www.sedermera.se) respective websites. Teaser and subscription forms will be published in connection with the start of the subscription period.

The subscription period runs until 30 March, 2017. Fully subscribed rights issue provides Oncology Venture with approximately SEK 52.9 million before issuing costs. Beforehand, the company has agreed on subscription commitments amounting to approximately SEK 18.9 million, of which Chairman of the board Duncan Moore invest 555 702 SEK, board member Peter Birk invest 12 726 SEK and board member Ulla Hald Buhl and VD Peter Buhl Jensen invest 1 275 162 SEK (via Buhl Krone Holding). The total amount equals to about 35.7 % of the rights issue’s total volume. The rights issue is also open to the public.

Financial advisor

Sedermera Fondkommission is the financial advisor to Oncology Venture in connection with the planned rights issue.

For questions related to the new issue, please contact:

Sedermera Fondkommission

Telephone: + 46 40-615 14 10

E-mail: info@sedermera.se

For further information about Oncology Venture, please contact:

This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 14 March 2017.

About Oncology Venture Sweden AB

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.

The current product portfolio: LiPlaCis for Breast Cancer, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.

Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates and Danish OV-SPV 2 will test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor.